Baricitinib showed mixed results in treating alopecia areata in children, with some improvement but also side effects.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
April 2024 in “DAHUDER Medical journal” The study concluded that there is no significant link between thyroid autoimmunity and alopecia areata.
November 2023 in “PubMed” Pentoxifylline is a safe and effective alternative to triamcinolone acetonide for treating localized alopecia areata.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” An integrated treatment approach effectively managed plaque psoriasis, leading to complete symptom resolution and hair regrowth.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” The document concludes that a new questionnaire to assess mental health in alopecia patients shows low rates of seeking mental health services and support groups.
56 citations
,
January 2019 in “Lancet” JAK inhibitors help regrow hair in alopecia areata patients, improving their quality of life.
45 citations
,
January 2013 in “Dermatology Research and Practice” Alopecia areata significantly worsens quality of life, suggesting a need for mental health support.
March 2025 in “Kerala Journal of Ayurveda” Ayurvedic treatments successfully regrew hair and reduced hair loss in a woman with alopecia areata.
March 2024 in “Clinical, cosmetic and investigational dermatology” Upadacitinib may effectively treat alopecia areata without side effects.
July 2021 in “The Egyptian Journal of Hospital Medicine” Intralesional Triamcinolone acetonide injections are safe and effective for treating alopecia areata.
3 citations
,
December 2018 in “Journal of Pakistan Association of Dermatology” Alopecia areata mainly affects young people, often showing as patchy hair loss on the scalp.
February 2019 in “IP Indian journal of clinical and experimental dermatology” Psychological stress is a major factor in the onset and severity of alopecia areata, with atopic individuals being more prone to develop it.
7 citations
,
January 2022 in “SAGE open medical case reports” Upadacitinib successfully treated a child's severe skin and hair loss issues.
182 citations
,
December 2017 in “Journal of the American Academy of Dermatology” Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.
1 citations
,
January 2025 in “CPT Pharmacometrics & Systems Pharmacology” Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
11 citations
,
December 2017 in “Orphanet Journal of Rare Diseases” A new mutation in the ST14 gene broadens the understanding of ichthyosis-hypotrichosis syndrome.
Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.
8 citations
,
January 2009 in “Pepperdine Digital Commons (Pepperdine University)” Athletes face unfair legal challenges in doping cases and need better support and representation.
September 2024 in “Annals of Medicine and Surgery” Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
11 citations
,
November 2019 in “Journal of the American Academy of Dermatology” Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
1 citations
,
October 2024 in “JAAD Case Reports” Baricitinib effectively treated hair loss and inflammation in a patient with alopecia areata and lichen planopilaris.
March 2005 in “Journal of the American Academy of Dermatology” Higher levels of IL-1a and IL-1RA were found in severe alopecia areata cases.
September 2025 in “Journal of the American Academy of Dermatology” Eyebrow and eyelash hair loss in alopecia areata worsens quality of life.
September 2023 in “Dermatology and Therapy” Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.
April 2026 in “Clinical and Translational Science” Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.
June 2025 in “The Journal of Dermatology” Baricitinib is effective and safe for long-term treatment of severe alopecia areata.
2 citations
,
September 2023 in “Journal of the Egyptian Womenʼs Dermatologic Society” Exclamation mark hairs and broken hairs best indicate active alopecia areata.
Combining baricitinib with golimumab helped regrow hair in a patient with ankylosing spondylitis and alopecia areata.